94 results about "Mouse Lung" patented technology

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention provides an alkaloid compound as well as a preparation method and an application thereof in tumor resistance. The alkaloid compound provided by the invention shows a remarkable cytotoxic effect on human non-small cell lung cancer cells A549, mouse lung adenocarcinoma cells Lewis, human triple negative breast cancer cells MDA-MB-231 and mouse breast cancer cells 4T1, and can be used for preparing medicines for treating breast cancer, lung cancer and the like.

The invention belongs to the technical field of medicines, and discloses a common goldenrop decoction active ingredient composition and application thereof in prevention and treatment of human respiratory syncytial virus. The invention relates to application of an active ingredient composition (isoliquiritigenin, baicalein, 6-shogaol, schisandrin B, ferulic acid and methyl salicylate) of Xiaochaihu decoction and / or a derivative of the active ingredient or a pharmaceutically acceptable salt thereof in preparation of medicines for preventing, relieving and / or treating RSV (Respiratory Syndrome Virus) infectious diseases. According to the invention, by establishing a mouse RSV infection model, the effect and the action mechanism of the composition in preventing and treating RSV infection are evaluated. Results show that each dose group can inhibit replication of RSV in mouse lung tissues, relieve pulmonary edema, improve pathological changes of the lung, inhibit expression of inflammatory factors and improve humoral immunity, and the effect is equivalent to that of ribavirin. The radix bupleuri granules have better effects on relieving pulmonary edema and inhibiting virus proliferation compared with small radix bupleuri granules. The composition of the effective components of the common goldenrop can provide a new drug treatment scheme for clinical RSV infectious diseases.

The invention discloses a mouse lung organ and fibroblast co-culture method, which comprises the following steps of: performing in-vitro mouse lung organ culture on mouse lung tissue primary epithelial stem cell spheres (pneumospheroids) in a Transwell upper chamber, and after the lung organs in the Transwell upper chamber are differentiated, replacing with a lower chamber paved with mouse lung fibroblasts, therefore, a gas-liquid interface co-culture system of the mouse lung organ (upper chamber) and the fibroblast (lower chamber) is formed, and the hierarchical structure, morphological characteristics and regeneration function of the upper chamber organ and the phenotype, function and related signal path activation level of the lower chamber fibroblast can be dynamically researched.

The invention provides a multi-element machine learning model-based cross-species lung disease characteristic gene screening method and system, an electronic system and a storage device. The method comprises the following steps of: acquiring single cell / transcriptome data related to mouse lung diseases from a public database and preprocessing the single cell / transcriptome data; training the model by adopting six machine learning algorithms and outputting a gene importance score; calculating the weight according to the model performance and normalizing the score; and integrating the cross-species scores through a weighted fusion formula, and outputting a feature gene list and a visual report. The system comprises a data acquisition and preprocessing module, a multi-element machine learning model training module, a weight calculation and normalization module, a cross-species comprehensive scoring module and a result output module. The screening accuracy, stability and generalization ability are improved through multi-algorithm integration and cross-species fusion, and the method can be widely applied to the fields of mechanism research of lung diseases, diagnosis marker development and drug target verification.

The invention discloses application of peimisine in preparation of an anti-fibrosis medicine, and belongs to the technical field of biological medicines. According to the application, mouse pulmonary interstitial fibrosis is induced through bleomycin, the treatment effect of peimine on pulmonary fibrosis is observed, and the influence of peimine on the pulmonary fibrosis process is explored. Results show that peimisine can reduce mouse lung index increase caused by bleomycin, improve damage of pulmonary alveolar structures of mice with pulmonary fibrosis, reduce aggregation of inflammatory cells, reduce serum fibrosis factors TGF-beta1 and inflammatory factors IL-2 of the mice with pulmonary fibrosis, and reduce the number of macrophages and neutrophils in BALF of the mice with pulmonary fibrosis. The peimisine has an obvious regulating effect on MRC-5 cell abnormal proliferation induced by TGF-beta1, can improve in-vivo pulmonary fibrosis induced by bleomycin by regulating the process of extracellular matrix and intercellular matrix, has an obvious treatment effect on mouse pulmonary fibrosis induced by bleomycin, is beneficial to development and utilization of peimisine, and has a good application prospect. And an effective method is provided for clinical treatment of pulmonary fibrosis.

This invention relates to the application of β-sitosterol glycoside in the preparation of products for treating lung cancer. This invention creatively provides a new use for the active monomer β-sitosterol glycoside, demonstrating that β-sitosterol glycoside can significantly inhibit the migration ability of lung cancer cells at doses without cell proliferation inhibitors, clarifying the specificity of its anti-metastatic effect, and laying the foundation for further new drug development of this monomer component. Through an in vivo mouse lung metastasis model, this invention demonstrates that β-sitosterol glycoside effectively inhibits the formation of lung metastases while exhibiting no significant toxic side effects in experimental animals, demonstrating high safety, and providing a new candidate molecule for the development of low-toxicity, highly effective anti-lung cancer metastasis drugs.

The invention discloses application of ceftriaxone sodium in preparation of a medicine for preventing and / or treating pulmonary nodules, and belongs to the technical field of tumor prevention and treatment, ceftriaxone sodium is converted into inhalable aerosol particles through an aerosol inhalation device, targeted delivery of the medicine to the lung can be achieved, systemic adverse reactions caused by systemic administration are remarkably reduced, and the curative effect of the medicine is improved. Therefore, the medicine has a treatment effect on pulmonary nodules. Experimental results in the early stage prove that ceftriaxone sodium with different concentrations is subjected to aerosol inhalation to intervene in a mouse pulmonary nodule model induced by uratan, and the ceftriaxone sodium has a good prevention and treatment effect. The research can provide new experimental basis and reference for development of lung nodule related prevention and treatment medicines, provides new technical ideas for prevention and treatment of other diseases, and has important academic value and potential of further development and research.

The invention discloses a plant lactobacillus AR195 strain and application thereof in preparation of a medicine for preventing and / or treating lung cancer, and belongs to the technical field of microorganisms. Through verification, the plant lactobacillus AR195 can inhibit the growth of lung cancer cells, also has certain prevention and treatment effects in a lung cancer mouse model, and can reduce the tumor burden of a BALB / c mouse lung cancer model by reducing MMP9 secretion, so that the plant lactobacillus AR195 can be used for preventing and assisting in treating lung cancer. Meanwhile, the accumulation of the AR195 bacteria in the lung can be improved to the maximum extent through atomization administration, and meanwhile, the adverse side effects of the whole body are reduced. A new drug source is provided for treatment of lung cancer, a novel treatment strategy is provided for treatment of lung cancer by probiotics, and treatment of lung cancer and development of a novel treatment method are facilitated. Meanwhile, the application range of the plant lactobacillus AR195 strain is widened, and a novel treatment strategy is provided for a potential mechanism of treating lung cancer by probiotics.

This invention belongs to the field of biomedical technology and discloses the application of KDELR3 inhibitors in the preparation of drugs for the prevention and / or treatment of individual fibrotic diseases. In a wild-type mouse model of pulmonary fibrosis, compared with the control group receiving intratracheal injection of Scr siRNA, intratracheal injection of KDELR3 siRNA significantly reduced the degree of fibrosis in the mouse lung tissue. KDELR3 inhibition significantly reduced collagen deposition and improved lung tissue structural damage. Further mechanistic studies showed that KDELR3 inhibitors can inhibit the differentiation of fibroblasts into myofibroblasts, thereby reducing the production of fibrosis-related extracellular matrix. These results indicate that KDELR3 is a key molecule regulating the occurrence and development of fibrosis, and drugs that can inhibit KDELR3 expression or activity can be used to prevent and treat various fibrotic diseases, including pulmonary fibrosis, laying the foundation for the development of novel drugs that are effective and safe in treating fibrotic diseases.

The application provides a method for constructing a mouse emphysema model and application, and the method comprises specifically knocking out a PHLDA1 gene in type II alveolar epithelial cells in lung tissue of an animal. Compared with a traditional method for establishing an animal mouse emphysema model by exposing to cigarette smoke, the mouse emphysema model has good stability, can be bred, has a short modeling cycle, and better simulates the lung tissue pathological changes and pathophysiological changes of emphysema patients, and has high consistency with the patients.

The application discloses application of a PRMT3 inhibitor SGC707 in preparation of a drug for treating pulmonary fibrosis, and for the first time verifies that a selective PRMT3 inhibitor SGC707 can dose-dependently inhibit expression of fibrosis markers such as COL1A1 and alpha-SMA in fibroblasts induced by TGF-beta 1 in vitro; in a bleomycin (BLM) induced mouse pulmonary fibrosis model, SGC707 administration can significantly improve lung tissue collagen deposition, reduce inflammatory cell infiltration, repair alveolar structure damage, and effectively down-regulate expression levels of fibrosis related proteins in lung tissues. It is proved that PRMT3 is a functional target with important intervention value in pulmonary fibrosis, SGC707 has definite anti-pulmonary fibrosis activity in vitro and in vivo, and a new drug strategy is provided for treatment of pulmonary fibrosis.

The present application relates to the technical field of content detection, in particular to a method for rapidly detecting the content of hydroxyproline in mouse lung tissue, which comprises the following steps: obtaining the original sampling spectrum of the lung tissue of the mouse to be detected at different preset sampling points, and obtaining a non-lung tissue interference characteristic base matrix containing whole blood characteristics and cartilage characteristics; setting an orthogonal filter operator and determining a lung interstitium characteristic spectrum vector; constructing a reference spectrum vector and determining a relative spectral response factor; constructing a spectral minimum spanning tree and determining a signal contribution weight based on the spectral minimum spanning tree and the relative spectral response factor; generating a whole lung fibrosis synthetic spectrum according to the signal contribution weight and the lung interstitium characteristic spectrum vector, and detecting the content of hydroxyproline based on the whole lung fibrosis synthetic spectrum. The present application considers the non-lung tissue interference containing whole blood characteristics and cartilage characteristics when detecting the content of hydroxyproline, which improves the rationality of the detection of the content of hydroxyproline to a certain extent.

The application discloses a new use of a BET inhibitor YD-851 or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating pulmonary fibrosis. The application finds that YD-851 can inhibit the expression of BRD4 and fibrosis-related markers in pulmonary fibrosis tissues, reduce the structural damage of bleomycin-induced mouse lung tissues, inflammatory cell infiltration and fibrosis pathological changes, and improve lung function damage. Experimental results show that YD-851 can reduce the pulmonary fibrosis score, inflammation score and area ratio of consolidation, improve the lung imaging abnormalities, and down-regulate the expression of fibrosis-related genes such as Col1a1, Fn1 and Acta2. It is shown that YD-851 has the effect of treating pulmonary fibrosis, and can be used for preparing a drug for treating pulmonary fibrosis, and a new use of YD-851 is developed.

The application provides a kind of antibiotic-loaded nanoemulsion and its preparation method and application, it is related to the technical field of medical adjuvant, antibiotic is mixed with medicinal adjuvant soybean oil, dipalmitoyl phosphatidylcholine and cholesterol, and volatile organic solvent is used to dissolve and form oil phase;Deoxycholic acid sodium and tween are dissolved in sterile liquid to form water phase;Oil phase and water phase are mixed, and are treated by ultrasonic treatment, rotary evaporation treatment and high pressure homogenization treatment, to obtain antibiotic-loaded nanoemulsion.The application adjusts the type of inhalable medicinal adjuvant, the addition ratio of inhalable medicinal adjuvant, the ratio of oil phase and water phase, and the ultrasonic power and homogenization pressure and other factors, so that the prepared nanoemulsion can efficiently load antibiotic, and has good aerosol inhalation performance, better drug stability, the nanoemulsion can be retained in mouse lung tissue for a long time, and the lung drug delivery efficiency is significantly improved.

A solution has been discovered that provides a more effective Coronavirus vaccine. The solution is an mRNA vaccine encoding a SARS-CoV-2 nucleoprotein (N) (mRNA-N) in combination with an mRNA vaccine encoding SARS-CoV-2 spike protein(S) (mRNA-S). Chemically modified mRNA-N (pseudouridine) and / or chemically modified mRNA-S (pseudouridine) can be synthesized and packaged in lipid nanoparticles (LNP). In mouse and hamster models, it was shown that mRNA-N alone is immunogenic and can significantly diminish viral loads in the mouse lung after prime-boost intramuscular immunization. In addition, the combinatorial mRNA-N / mRNA-S vaccination induces substantially stronger protection against SARS-CoV-2 than vaccination with mRNA-S alone.

This invention provides the application of huperzine A in the preparation of drugs for the prevention and / or treatment of pulmonary fibrosis. Using a bleomycin-induced in vitro pulmonary fibrosis model, this invention demonstrates that huperzine A can act as an aryl hydrocarbon receptor agonist, increasing the intracellular expression of aryl hydrocarbon receptors; using a bleomycin-induced mouse pulmonary fibrosis model, this invention demonstrates that huperzine A possesses anti-pulmonary fibrosis pharmacological activity. By studying the in vivo and in vitro bioactivity of huperzine A in the treatment of pulmonary fibrosis, this invention provides new ideas and solutions for the research and development and production of anti-fibrotic drugs.

The application belongs to the technical field of medicine, and discloses application of a perilla leaf extract in preparation of a medicine for treating and / or preventing asthma-chronic obstructive pulmonary disease (ACO). The perilla leaf extract has a significant curative effect in treating and / or preventing ACO disease, can significantly improve aggregation of inflammatory cells in the lung of an ACO mouse and generation levels of inflammatory factors, and improve lung function and pathological changes of lung tissue inflammation; in addition, the perilla leaf extract can significantly inhibit generation of neutrophil inflammatory factors TNF-alpha, IL-6 and IL-1beta, and inhibit generation of an eosinophil inflammatory factor TNF-alpha.

The invention relates to an application of Fgl2 gene knockout in antagonism of new coronavirus. In the technical scheme provided by the invention, a new crown infected mouse model is established through two SARS-CoV-2 mouse adaptive strains, namely, an MA17 strain and an MASCp36 strain, and it is verified that virus infection can promote Fgl2 expression up-regulation and fibrinogen deposition in mouse lung tissues; in addition, an SARS-CoV-2 mouse adaptive strain MA17 is utilized to infect an Fgl2 gene knockout mouse to prove that the Fgl2 gene knockout can antagonize lung inflammation infiltration, tissue damage, thromboembolism, fibrinogen deposition and fibrosis formation caused by virus infection, so that the occurrence of severe case and death of the mouse is reduced.

The invention belongs to the technical field of microorganisms, and particularly relates to multi-drug-resistant klebsiella pneumoniae and application thereof in construction of a pneumonia animal model. Specifically, the multi-drug-resistant klebsiella pneumoniae BKP919 provided by the invention is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.36301, and the multi-drug-resistant klebsiella pneumoniae BKP919 has wide drug resistance to various antibiotics such as amoxicillin, piperacillin and the like. The bacterial liquid of the strain is used for carrying out one-time intratracheal instillation on a mouse in a nasal instillation manner, and a stable severe pneumonia model can be established within 48-72 hours. The model preparation method is simple to operate and high in efficiency, and the model mouse has remarkable pneumonia symptoms, obvious pathological change and good related index stability, and can be used for pathogenesis research and targeted drug development of multi-drug-resistant klebsiella pneumonia infected pneumonia, so that the model has good practical application value.

The invention discloses an application of a small molecule drug ATWLPPR Peptide TFA in resisting mycobacterium bovis infection, and belongs to the field of biological medicine, the small molecule drug ATWLPPR Peptide TFA is an agonist of a target host factor NRP1, and then the inhibition effect of the ATWLPPR Peptide TFA on mycobacterium bovis in vitro and in vivo is researched. An in-vitro bacterial loading titration result shows that the ATWLPPR Peptide TFA treatment can present dose-dependent inhibition of the mycobacterium bovis to adhere to A549 cells. Mouse experiment results show that ATWLPPR Peptide TFA treatment can inhibit mice from being infected with mycobacterium bovis, pathological injuries of mouse lung tissues are effectively relieved, and a brand new direction is provided for prevention and control of mycobacterium bovis.

The invention relates to the field of traditional Chinese medicines, in particular to novel application of a Sweeping Tianhu lung-clearing and cough-relieving composition in treatment of chronic obstructive pulmonary disease. Animal experiment studies show that the Sweetio lung-clearing and cough-relieving composition can significantly improve the lung function of COPD mice and inhibit bronchial abnormal remodeling. The action mechanism of the composition is related to inhibition of lung tissue cell apoptosis, alleviation of inflammatory cell infiltration and improvement of abnormal remodeling of bronchus, which indicates that the Sweeping Litu composition for clearing away lung-heat and relieving cough has obvious pharmacological activity of resisting COPD (chronic obstructive pulmonary disease).

This invention discloses the application of a peptide SRD in the preparation of drugs for treating acute lung injury, belonging to the field of biomedical technology. In vivo experiments verified the protective effect of peptide SRD on acute lung injury (ALI), particularly its effect on improving AT2 mitochondrial function. In animal models of ALI, tail vein injection of peptide SRD significantly reduced the protein concentration and total cell count in bronchoalveolar lavage fluid, significantly alleviated the severity of lung injury, lowered histological scores, significantly decreased SOD2 acetylation levels while significantly increasing total SOD2 protein levels, and significantly increased SPC levels (an indicator of AT2 survival). ELISA analysis showed a significant decrease in the levels of IL-6, IL-1β, and TNF-α, indicators of pneumonia in mice. These experimental results confirm that the antioxidant peptide SRD can improve oxidative stress damage in ALI, effectively reduce AT2 cell damage under ALI conditions, promote AT2 regeneration and repair, effectively improve lung function, and reduce the inflammatory response of damaged lungs, thus exhibiting a good therapeutic effect on ALI.

The invention provides a construction method and application of a coxsackie virus susceptible animal model, and aims to improve the problem that coxsackie virus is not easy to feel in a conventional animal model, high expression of hKREMEN1 gene on mouse pulmonary epithelium is realized by using a gene editing technology, and the coxsackie virus susceptible animal model is obtained by constructing a mouse stably expressing an hKREMEN1 receptor. The infection ability of the coxsackie virus on mice is improved, a good foundation is laid for research and development of hand-foot-and-mouth disease vaccines, and vaccine preparation and effectiveness evaluation are facilitated.

This invention discloses a three-dimensional visualization method for pulmonary vessels based on light-sheet fluorescence microscopy, belonging to the field of three-dimensional imaging technology. It solves the problem of low spatial resolution in existing imaging and ultrasound examination equipment. The method includes endotracheal intubation of mice, subcutaneous injection of Cy7 solution for staining, dehydration of mouse lung tissue using gradient concentration tetrahydrofuran solution, and defatting with dichloromethane to make the sample nearly transparent. A light-sheet fluorescence microscopy system is then used to perform three-dimensional imaging of the lung tissue. This invention, through fluorescence excitation and acquisition in the infrared II band, can achieve higher imaging depth of the pulmonary vascular system, and deeper imaging offers better axial resolution, signal-to-background ratio, and contrast. Numerous two-dimensional image slices can be integrated and reconstructed to form an intuitive and complete three-dimensional visualization model of the pulmonary vessels. By quantifying the three-dimensional model, the fine structural changes of the pulmonary vessels can be observed more accurately.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of a ginseng and astragalus hypoglycemic preparation in preparation of medicines for preventing or treating pulmonary fibrosis. Pharmacodynamics shows that the ginseng and astragalus hypoglycemic granules can remarkably reduce expression of TGF-beta1, p-Smad3, p-P38MAPK and CollagenIII protein of diabetic pulmonary fibrosis model rat lung tissue, can effectively improve the pulmonary function and pulmonary fibrosis of diabetic mice, and have a remarkable protection effect on the diabetic mice lung tissue. The ginseng and astragalus hypoglycemic preparation can obviously reduce the expression of inflammatory factors TNF-alpha, IL-1beta and IL-6 of pulmonary fibrosis model mice, improve the SOD activity of mouse lung tissues and the T-AOC level of serum, and reduce the MDA level of the mouse lung tissues; the medicine can be used for treating pulmonary fibrosis. Meanwhile, the ginseng and astragalus hypoglycemic preparation is high in safety and small in toxic and side effects, and the clinical medication selection of patients is enriched.

The invention discloses a preparation and detection method of a mouse cough model induced by diesel tail gas particulate matters, and belongs to the field of biological medicines. Comprising the following steps: preparing a diesel tail gas particulate matter solution DEP; the method comprises the following steps: anesthetizing a mouse, suspending the mouse in a dissecting plate after the mouse is anesthetized, opening an airway by using tweezers, pulling open a tongue, pinching a nose, observing the breath of the mouse, placing a hose needle into the airway, and injecting a diesel tail gas particulate matter solution DEP into a rear airway of the mouse in a tracheal instillation manner when a gas phase is to be inhaled; observing the breath of the mouse and whether the lung of the mouse has wet rale or not, wherein the injection is successful if the wet rale appears; and putting the mouse back into the cage after resuscitation. The prepared and constructed mouse model can effectively simulate the cough symptom caused by diesel exhaust particles, the mouse model can show a stable cough model after DEP induction, and the mouse model is suitable for clarification of a cough mechanism induced by exposure of real particulate matters.

The invention belongs to the technical field of biological medicines, and discloses a cyclized antibacterial peptide CycP-1 targeting multiple drug-resistant klebsiella pneumoniae, and a composition and application thereof. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO.1, cysteine residues at the first site and the 24th site in a molecule of the antibacterial peptide form a disulfide bond, and the antibacterial peptide is in cyclization conformation and shows good in-vitro protease stability. Experiments show that the antibacterial peptide has a remarkable inhibiting effect on multi-drug-resistant and pan-drug-resistant klebsiella pneumoniae, and when the antibacterial peptide is combined with antibiotics, the antibacterial effect can be enhanced, drug resistance can be reversed or reduced, and generation of drug resistance can be delayed. A mouse pneumonia model in-vivo experiment further proves that after oral administration of the antibacterial peptide, the lung tissue bacterial load of a pan-drug resistant klebsiella pneumonia infected mouse can be remarkably reduced, lung pathological injury is relieved, the survival rate of the infected mouse is remarkably increased, and the effect is better when the antibacterial peptide is combined with polymyxin B.

This invention provides a neutralizing monoclonal antibody B36B9 against orthopoxvirus and its applications. The monoclonal antibody, obtained through flow cytometry sorting and single-cell PCR, possesses a unique CDR region and primarily recognizes the L1R (M1R) antigen protein of orthopoxvirus. The antibody exhibits affinities of 0.21 nM, 0.39 nM, 0.03 nM, and 0.12 nM for VARV, VACV, CPXV, and MPXV, respectively. In virus neutralization experiments, the antibody showed an IC50 value of [missing information - likely related to viral neutralization]. 50 The titer was 41.13 nM. In a mouse model of monkeypox virus infection, the antibody significantly reduced the viral titer in the lungs of mice. The monoclonal antibody provided by this invention has the characteristics of high expression, high affinity, and broad spectrum, and has the potential for application in the preparation of therapeutic and preventive drugs for monkeypox virus or kits for detecting monkeypox virus.